US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>HeartFlow is offering 12.5 million shares at a $15-$17 range which equates to a valuation of around $1.32 billion. </li>
<li>According to guidance the deal is being classified as oversubscribed with early long-only and healthcare dedicated conversions. </li>
<li>Combine durable revenues, strong underwriting and backers with a tailwind from a healthcare segment with a touch of AI, it is our opinion that this IPO will be well-received.</li>
</ul>


HeartFlow is offering 12.5 million shares at a $15-$17 range which equates to a valuation of around $1.32 billion. 
According to guidance the deal is being classified as oversubscribed with early long-only and healthcare dedicated conversions. 
Combine durable revenues, strong underwriting and backers with a tailwind from a healthcare segment with a touch of AI, it is our opinion that this IPO will be well-received.


HeartFlow Inc. (HTFL): Revenue Growth, Strong Margin Profile Highlights IPO Bull Case

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>HeartFlow submitted its prospectus, targeting a valuation of up to US$1.32 billion in US IPO. Heartflow is seeking up to US$212.5 million by offering 12.5 million shares priced between US$15-17/share.</li>
<li>HeartFlow’s moat includes a first-mover advantage, medical insurance network, and ecological cooperation with equipment manufacturers. However, the accuracy of its products is slightly inferior to that of similar Chinese products.</li>
<li>Our forecast is revenue to up 35% YoY/30% YoY/25% YoY in 2025/2026/2027. HeartFlow may achieve breakeven in 2027. Comfortable valuation could be P/S of 7-9x if based on 2025E revenue.</li>
</ul>


HeartFlow submitted its prospectus, targeting a valuation of up to US$1.32 billion in US IPO. Heartflow is seeking up to US$212.5 million by offering 12.5 million shares priced between US$15-17/share.
HeartFlow’s moat includes a first-mover advantage, medical insurance network, and ecological cooperation with equipment manufacturers. However, the accuracy of its products is slightly inferior to that of similar Chinese products.
Our forecast is revenue to up 35% YoY/30% YoY/25% YoY in 2025/2026/2027. HeartFlow may achieve breakeven in 2027. Comfortable valuation could be P/S of 7-9x if based on 2025E revenue.


Pre-IPO Heartflow (HTFL US - Thoughts on the Business and Valuation Outlook

<ul>
<li>Heartflow is offering 12.5 million shares at a $15-$17 range which equates to a valuation of around $1.32 billion.</li>
<li>They expect revenue for the three months ended June 30, 2025 to be approximately $42.9 million to $43.4 million, as compared to $31.1 million for the same period in 2024.</li>
<li>Heartflow is scheduled to debut on Friday, August 8th. We anticipate the offering to be "well-received". </li>
</ul>


Heartflow is offering 12.5 million shares at a $15-$17 range which equates to a valuation of around $1.32 billion.
They expect revenue for the three months ended June 30, 2025 to be approximately $42.9 million to $43.4 million, as compared to $31.1 million for the same period in 2024.
Heartflow is scheduled to debut on Friday, August 8th. We anticipate the offering to be "well-received". 


HeartFlow Inc. (HTFL): Coronary Artery Disease Company Sets Terms Seeking up to $1.3b Valuation

<ul>
<li>Heartflow seeks to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease.</li>
<li>As of March 31, 2025, their Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.</li>
<li>They had revenue of $87.2 million and $125.9 million and net loss of $95.7 million and $96.4 million in 2023 and 2024, respectively.</li>
</ul>


Heartflow seeks to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease.
As of March 31, 2025, their Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.
They had revenue of $87.2 million and $125.9 million and net loss of $95.7 million and $96.4 million in 2023 and 2024, respectively.


HeartFlow Inc. (HTFL): Peeking at the IPO Prospectus of Coronary Artery Disease Patient Care Company

United States

Heartflow, Inc. operates as a medical technology company. The Company develops an AI-driven coronary artery disease management platform that creates personalized, precision 3D model of the heart from a single computed tomography scan. HeartFlow serves patients and customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Heartflow (HTFL US)

HeartFlow Inc. (HTFL): Revenue Growth, Strong Margin Profile Highlights IPO Bull Case

HeartFlow plans to offer 12.5 million shares at a $15-$17 range. The IPO is expected to be oversubscribed, backed by strong underwriting and a...

IPO Boutique

Pre-IPO Heartflow (HTFL US - Thoughts on the Business and Valuation Outlook

Heartflow is seeking $212.5mn by offering 12.5mn shares priced between $15-17.Revenue forecasted to grow steadily, potential breakeven in...

Xinyao (Criss) Wang

HeartFlow Inc. (HTFL): Coronary Artery Disease Company Sets Terms Seeking up to $1.3b Valuation

Heartflow is set to debut with 12.5 million shares at a $15-$17 range, expecting a valuation of $1.32 billion and strong revenue growth.

IPO Boutique

HeartFlow Inc. (HTFL): Peeking at the IPO Prospectus of Coronary Artery Disease Patient Care Company

Heartflow's non-invasive solution for diagnosing coronary artery disease has been used in over 400,000 patients, with significant revenue and net...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

HeartFlow Inc. (HTFL): Revenue Growth, Strong Margin Profile Highlights IPO Bull Case

​HeartFlow plans to offer 12.5 million shares at a $15-$17 range. The IPO is expected to be oversubscribed, backed by strong underwriting and a...

IPO Boutique

Pre-IPO Heartflow (HTFL US - Thoughts on the Business and Valuation Outlook

Heartflow is seeking $212.5mn by offering 12.5mn shares priced between $15-17.Revenue forecasted to grow steadily, potential breakeven in...

Xinyao (Criss) Wang

HeartFlow Inc. (HTFL): Coronary Artery Disease Company Sets Terms Seeking up to $1.3b Valuation

​Heartflow is set to debut with 12.5 million shares at a $15-$17 range, expecting a valuation of $1.32 billion and strong revenue growth.

IPO Boutique

HeartFlow Inc. (HTFL): Peeking at the IPO Prospectus of Coronary Artery Disease Patient Care Company

​Heartflow's non-invasive solution for diagnosing coronary artery disease has been used in over 400,000 patients, with significant revenue and net...

IPO Boutique

HeartFlow plans to offer 12.5 million shares at a $15-$17 range. The IPO is expected to be oversubscribed, backed by strong underwriting and a...

Heartflow is set to debut with 12.5 million shares at a $15-$17 range, expecting a valuation of $1.32 billion and strong revenue growth.

Heartflow's non-invasive solution for diagnosing coronary artery disease has been used in over 400,000 patients, with significant revenue and net...